A detailed history of Nuveen Asset Management, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 313,307 shares of ABUS stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
313,307
Previous 313,307 -0.0%
Holding current value
$1.08 Million
Previous $968,000 24.59%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$2.52 - $3.63 $48,260 - $69,518
19,151 Added 6.51%
313,307 $968,000
Q4 2023

Feb 14, 2024

BUY
$1.69 - $2.54 $3,606 - $5,420
2,134 Added 0.73%
294,156 $735,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $2.27 $3,231 - $3,861
-1,701 Reduced 0.58%
292,022 $592,000
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $43,155 - $58,953
19,266 Added 7.02%
293,723 $675,000
Q1 2023

May 15, 2023

SELL
$2.23 - $3.1 $34,886 - $48,496
-15,644 Reduced 5.39%
274,457 $831,000
Q4 2022

Feb 14, 2023

SELL
$1.91 - $2.85 $68,834 - $102,711
-36,039 Reduced 11.05%
290,101 $675,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $2,227 - $3,412
-1,185 Reduced 0.36%
326,140 $623,000
Q2 2022

Aug 15, 2022

SELL
$1.98 - $3.17 $2.53 Million - $4.05 Million
-1,278,189 Reduced 79.61%
327,325 $887,000
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $983,233 - $1.62 Million
-406,295 Reduced 20.2%
1,605,514 $4.62 Million
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $2.77 Million - $4.11 Million
892,198 Added 79.69%
2,011,809 $7.89 Million
Q3 2021

Nov 12, 2021

BUY
$2.65 - $4.62 $2.37 Million - $4.13 Million
893,599 Added 395.38%
1,119,611 $4.87 Million
Q2 2021

Aug 16, 2021

BUY
$2.5 - $3.51 $565,030 - $793,302
226,012 New
226,012 $685,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $516M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.